NCI Community Oncology Research Program - Kansas City (NCORP-KC)
NCI Community Oncology Research Program - Kansas City (NCORP-KC)




NCI Community Oncology Research Program - Protocol Summary

RTOG 1112 - "RANDOMIZED PHASE III STUDY OF SORAFENIB VERSUS STEREOTACTIC BODY RADIATION THERAPY FOLLOWED BY SORAFENIB IN HEPATOCELLULAR CARCINOMA"

The summary below serves as a brief review of the treatment plan and eligibility for the protocol.


This summary is not intended to be used in place of the full eligibility & treatment information in the protocol.
 

Please follow the "Full Protocol" link or contact NCORP-KC for complete protocol information.



Print This Summary

GI Clinical Trial

CANCER TYPE: Liver
RESEARCH BASE: NRG
NCT NUMBER: NCT01730937
HIPPA FORM: DOWNLOAD HIPPA FORM

Consent Form: VIEW CONSENT FORM

BRIEF DESCRIPTION

HCC, BCLC stage Intermediate (B) or advanced (C), Sorafenib alone VS. SBRT + Sorafenib.  DCP-001 Eligible



NOTES


Treatment Plan         (Provided drug:  none)

Arm 1

Day 1-Start Sorafenib 400mg BID daily (Dose level 0). Each cycle=28 continuous days until progression, toxicity or 5 years

Arm 2

SBRT delivered over 5 fractions delivered over 5-15 days.  The prescription dose may be 50 Gy, 45 Gy, 40 Gy, 35 Gy, 30 Gy or 27.5 Gy in 5 fractions, based on normal tissue constraints.

Sorafenib to start Day 1-5 post SBRT completion at 200mg BID (level -1). Each cycle=28 days until progression, toxicity or 5 years
Sorafenib will be increased to 400mg BID during cycle #2 if clinically appropriate, as per Section 7.1.1.



ELIGIBILITY

  • Patients must have an HCC diagnosis (initial, recurrent, progressive and/or refractory to other therapies) by at least one criterion listed below ≤360 days prior to study entry
    • Pathologically (histologically or cytologically) proven diagnosis of HCC.
    • At least one solid liver lesion or vascular tumor thrombosis (involving portal vein, IVC and/or hepatic vein) > 1 cm with arterial enhancement and delayed washout on multi-phasic computerized tomography (CT) or magnetic resonance imaging (MRI) in the setting of cirrhosis or chronic hepatitis B or C without cirrhosis.
    • For patients whose CURRENT disease is vascular only:
      Enhancing vascular thrombosis (involving portal vein, IVC and/or hepatic vein) demonstrating early arterial enhancement and delayed washout on multi-phasic CT or MRI, in a patient with known HCC (diagnosed previously < 720 days)
  • Measureable hepatic disease and/or presence of vascular tumor thrombosis (involving portal vein, IVC and/or hepatic vein) which may not be measureable as per RECIST, as defined in Section 11.0) on liver CT or MRI, within 28 days of registration
  • Appropriate for protocol entry based upon the following minimum diagnostic workup:
    • History/physical examination including examination for encephalopathy, ascites, weight, height, and blood pressure within 14 days prior to study entry
    • Assessment by radiation oncologist and medical oncologist or hepatologist who specializes in treatment of HCC within 28 days prior to study entry
    • Pre-randomization Scan (REQUIRED for All Patients): CT scan chest/abdomen/pelvis with multiphasic liver CT or multiphasic liver MR scan within 28 days prior to study entry. MRI of abdomen with contrast and pelvis is permitted. See Appendix V and Section 4.1.7 for details.
  • Zubrod Performance Status 0-2 within 28 days prior to study entry
  • Age ≥ 18
  • All blood work obtained within 14 days prior to study entry with adequate organ marrow function defined as follows:
    • Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3
    • Platelets ≥ 70,000 cells/mm3
    • Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable.)
    • Total bilirubin < 2 mg/dL
    • Internationalized Normal Ratio (INR) < 1.7
    • Albumin ≥ 28 g/L
    • AST and ALT < 6 times ULN
    • Serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 60 mL/min
  • BCLC stage: Intermediate (B) or advanced (C) within 14 days prior to study entry
  • Child-Pugh score A within 14 days prior to study entry
  • Women of childbearing potential and male participants must agree to practice adequate contraception while on study and for at least 6 months following the last dose of RT and for at least 28 days following the last dose of sorafenib (whichever is later).
  • Unsuitable for resection or transplant or radiofrequency ablation (RFA)
  • Unsuitable for or refractory to transarterial hepatic chemo-embolization (TACE) or drug eluting beads (DEB) for any of the following reasons, as described by Raoul et al (2011):
    • Technical contraindications: arteriovenous fistula, including surgical portosystemic shunt or spontaneous portosystemic shunt
    • Severe reduction in portal vein flow: due to tumor portal vein, IVC or atrial invasion or bland portal vein occlusion
    • Medical contraindications including congestive heart failure, angina, severe peripheral vascular disease
    • Presence of extrahepatic disease
    • No response post TACE (or DEB) or progressive HCC despite TACE. Prior TACE or DEB is allowed but must be > 28 days from study entry
    • Serious toxicity following prior TACE (or DEB). Prior TACE or DEB must be > 28 days from study entry
    • Other medical comorbidities making TACE (or DEB) unsafe and/or risky (e.g. combination of relative contraindications including age > 80 years, tumor > 10 cm, > 50% replacement of the liver by HCC, extensive multinodular bilobar HCC, biliary drainage)
  • Patients treated with prior surgery are eligible for this study if they otherwise meet eligibility criteria.
  • Patient must be able to provide study-specific informed consent prior to study entry.
  • No prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 2 years (Note that carcinoma in situ of the breast, oral cavity, or cervix are all permissible)
  • No prior sorafenib use > 60 days. Note that prior chemotherapy for HCC or a different cancer is allowable. See Section 3.2.1.
  • No prior radiotherapy to the region of the liver that would result in excessive doses to normal tissues due to overlap of radiation therapy fields
  • No prior selective internal radiotherapy/hepatic arterial Yttrium therapy, at any time
  • No severe, active co-morbidity, defined as follows:
    • Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months before registration
    • Transmural myocardial infarction within the last 6 months prior to study entry
    • Unstable ventricular arrhythmia within the last 6 months prior to study entry
    • Acute bacterial or fungal infection requiring intravenous antibiotics within 28 days prior to study entry
    • Hepatic insufficiency resulting in clinical jaundice, encephalopathy and/or variceal bleed within 60 days prior to study entry
    • Bleeding within 60 days prior to study entry due to any cause, requiring transfusion
    • Thrombolytic therapy within 28 days prior to study entry. Subcutaneous heparin is permitted.
    • Known bleeding or clotting disorder
    • Uncontrolled psychotic disorder
  • No pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.
  • No hepatocellular carcinoma > 15 cm
  • Total maximal sum of hepatocellular carcinomas or a single conglomerate HCC cannot be greater than 20 cm
  • Cannot have more than 5 discrete intrahepatic parenchymal foci of HCC
  • No direct tumor extension into the stomach, duodenum, small bowel or large bowel
  • No measureable common or main branch biliary duct involvement with HCC
  • No extrahepatic metastases or malignant nodes (that enhance with typical features of HCC) > 3.0cm, in sum of maximal diameters (e.g. presence of one 3.4 cm metastatic lymph node or two 2 cm lung lesions). Note that benign non-enhancing periportal lymphadenopathy is not unusual in the presence of hepatitis and is permitted, even if the sum of enlarged nodes is > 2.0 cm.
  • No use of regular phenytoin, carbamzepine, hypericum perforatum [also known as St. John’s wort] or rifampin
  • No use of combination anti-retroviral therapy for HIV, as these agents may modulate cytochrome P450 isozymes
  • No prior liver transplant





  © 2013-2018 All Rights Reserved. Privacy Policy | Terms & Conditions
NCI Community Oncology Research Program - Kansas City (NCORP-KC)
Questions? Call: +1-913-948-5588 | Contact Us
4121 W. 83rd St., Suite 259 Prairie Village, KS 66208 USA